Research & Innovation

Multiple Myeloma Clinical Trials

Clinical Trials

Connect MM Registry / CC-5013-MM-036

Connect MM: The Multiple Myeloma Disease Registry (Cohort 3)

Physician & Study Coordinator

Study Coordinator

Carolyn Seith
phone: 484-658-1789




This is an observational research, or registry study that is non-interventional. The purpose of the research is to understand treatment patterns and the effectiveness of drugs used in the treatment of Multiple Myeloma. This registry previously involved two groups (Cohort 1 and Cohort 2) with newly diagnosed Multiple Myeloma. Cohort 3 will enroll participants with relapsed/refractory Multiple Myeloma who have received prior therapy for Multiple Myeloma.


Eligibility Criteria
  • Patients must be at least 18 years of age at time of initial diagnosis of symptomatic Multiple Myeloma (MM)
  • Patients must be able and willing to complete patient assessment questionnaires either alone or with minimal assistance from caregivers and/or trained site personnel
  • Patients must have received prior 1st line therapy for symptomatic active MM and subsequently have evidence of clinical disease progression that warrants 2nd line treatment
  • Patients must have started 2nd line therapy after the first relapsed/refractory diagnosis date OR intend to start 2nd line therapy shortly after enrollment on this registry
  • Patients must have started 2nd line therapy and be enrolled on study within 60 days of the first relapse/disease progression date
  • Patients may not be receiving an investigational product as part of their therapy for MM